Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

MDR

- PMLiVE

Cubist gets green light from FDA for new antibiotic Sivextro

First drug approved under qualified infectious disease product framework

- PMLiVE

Pfizer turns to cancer immunotherapies

Signs deal with French company Cellectis

- PMLiVE

Pfizer appoints diabetes expert Morris Birnbaum

He takes up post as chief scientific officer for cardiovascular and metabolic diseases

- PMLiVE

FDA fast-tracks new AstraZeneca antibiotic

Speeds up review period for AZD0914 in gonorrhoea

- PMLiVE

Pfizer abandons AZ takeover bid – for now

Deadline for deal passes after four rejected offers

- PMLiVE

No mass revolt from AZ shareholders on Pfizer takeover

Company’s decision to stand firm is applauded by investors

- PMLiVE

Nothing makes sense

Evolutionary theory helps us understand and adapt to the current deal-making frenzy

- PMLiVE

Unions blast ‘negative consequences’ for Sweden of a Pfizer-AZ deal

Say proposed takeover posed an imminent risk to country's life science sector

- PMLiVE

AstraZeneca rejects ‘final offer’ from Pfizer

And US pharma company rules out hostile takeover

- PMLiVE

MPs grill Read over Pfizer’s commitments to UK

CEO faces combative parliamentary hearing over AstraZeneca bid

GW hires Pfizer’s Kenneth Sommerville

Appointed VP clinical research at company specialising in cannabinoids

- PMLiVE

AZ circles wagons as Pfizer hints at hostile takeover

Aims for annual revenues of $45bn by 2023

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links